Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Tom Frohlich is Chief Executive Officer at Jade Biosciences. OQRO lists 1 transaction filed with the SEC under this name, the latest on May 19, 2025, each linked to the official Form 4.
Chief Executive Officer
Disclosures on record
1
Companies involved
1
Jade BiosciencesJBIO
May 16, 2025Bought~$44Kdisclosed May 19
DetailsOfficial recordAs of the latest filing on , Tom Frohlich reported holding 6,000 shares of Jade Biosciences (JBIO), worth about $97K at the last close of $16 (Nov 13, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Jade Biosciences JBIO | 6,000 | 6,000 direct | $16 | $97K | May 16, 2025 |
Is this Tom Frohlich’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Tom Frohlich bought shares on the open market in 2025.
Tom Frohlich reported 1 open-market purchase and 0 sales since 2025; purchases in 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $44K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated May 16, 2025, Tom Frohlich reported holding 6,000 shares of Jade Biosciences (JBIO). At the last close of $16 on Nov 13, 2026, that is about $97K. This is the stake disclosed in filings, not a net worth.
Tom Frohlich bought shares on the open market in 2025.
In SEC filings since 2025: the latest open-market purchase is from 2025; no open-market sale is on record.
Jade Biosciences (JBIO), from 2025 to 2025: 1 purchase and 0 sales.
Tom Frohlich reported 1 open-market purchase and 0 sales here, 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
